Linked Data API

Show Search Form

Search Results

1715830
registered interest false remove filter
date less than 2024-05-03more like thismore than 2024-05-03
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Hormones: Sales more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on steps to (a) tackle the illegal sale of cross-sex hormones online and (b) protect public health. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 24802 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-09more like thismore than 2024-05-09
answer text <p>Strict regulatory controls govern medicinal products for human use, including their manufacture, distribution, retail sale and supply, and advertisement. The medicines referred to cannot be advertised directly to the public, and any online offer to sell or supply them to a patient would likely contravene the Human Medicines Regulations 2012.</p><p>Instances of United Kingdom-based non-compliant activity relating to the online advertising, sale, or supply of medicines are reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) on a case-by-case basis, and appropriate action taken. Enforcement options include removal of the offending weblink, remedial intervention to bring the owner into compliance, or a criminal investigation and possible prosecution.</p><p>The MHRA also works closely with partners to prevent medicines from entering or being traded in the UK illegally. The MHRA’s Fake Meds campaign encourages people in the UK to use safe and legitimate sources when buying medication online. The MHRA also promotes the reporting of suspicious medicinal products and adverse side effects via its Yellow Card scheme. Further information on the Fake Meds campaign and the Yellow Card scheme is available, respectively, at the following links:</p><p><a href="https://fakemeds.campaign.gov.uk/" target="_blank">https://fakemeds.campaign.gov.uk/</a></p><p><a href="https://yellowcard.mhra.gov.uk/" target="_blank">https://yellowcard.mhra.gov.uk/</a></p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-05-09T13:10:41.723Zmore like thismore than 2024-05-09T13:10:41.723Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1715833
registered interest false remove filter
date less than 2024-05-03more like thismore than 2024-05-03
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Prescription Drugs: Sales more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he plans to bring forward legislative proposals to tackle the online sale of prescription-only medications without a prescription. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 24803 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-14more like thismore than 2024-05-14
answer text <p>The sale and supply of prescription-only medicines is regulated by the Human Medicines Regulations 2012 (HMR). The HMR provides inspection and enforcement powers for the Medicines and Healthcare products Regulatory Agency, and creates criminal offences in respect of non-compliance with those regulations. At this time, the Department has no plans to legislate the online sale of prescription-only medicines without a prescription.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-05-14T16:37:59.003Zmore like thismore than 2024-05-14T16:37:59.003Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1702405
registered interest false remove filter
date less than 2024-04-19more like thismore than 2024-04-19
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Clinical Trials: Children more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure (a) transparency and (b) parental consent in clinical trials involving children. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 22789 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-24more like thismore than 2024-04-24
answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
grouped question UIN 22790 more like this
question first answered
less than 2024-04-24T16:22:38.813Zmore like thismore than 2024-04-24T16:22:38.813Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1702406
registered interest false remove filter
date less than 2024-04-19more like thismore than 2024-04-19
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Clinical Trials more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what measures are in place to ensure informed consent in clinical trials. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 22790 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-24more like thismore than 2024-04-24
answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
grouped question UIN 22789 more like this
question first answered
less than 2024-04-24T16:22:38.76Zmore like thismore than 2024-04-24T16:22:38.76Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1702197
registered interest false remove filter
date less than 2024-04-18more like thismore than 2024-04-18
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Strikes (Minimum Service Levels) Act 2023 more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the impact of the Strikes (Minimum Service Levels) Act 2023 on the ability of healthcare professionals to participate in industrial action. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 22623 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-23more like thismore than 2024-04-23
answer text <p>The Strikes (Minimum Service Levels) Act 2023 allows for regulations to be laid in Parliament in the health sector. The Strikes (Minimum Service Levels: NHS Ambulance Services and the NHS Patient Transport Service) Regulations 2023 came into force on 8 December 2023.</p><p>As we set out in in our consultation response on minimum service levels in the ambulance sector, in our engagement with representatives from ambulance trusts, they indicated that establishing a minimum service level at the level specified in the regulations would require approximately 80% of an ambulance service’s resources on a typical shift. Therefore, if an employer chose to issue work notices during a strike, it is likely that a high proportion of all levels of paramedics, emergency care assistants, and other staff in the ambulance teams rostered to work on a strike would be named, and this would have a significant impact on the ability of employees to participate in strike action. The Department has consulted on whether to implement similar regulations for hospital services, and will set out its response in due course.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-04-23T13:48:18.007Zmore like thismore than 2024-04-23T13:48:18.007Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1702199
registered interest false remove filter
date less than 2024-04-18more like thismore than 2024-04-18
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Strikes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions she has had with healthcare professionals on minimum service levels during strikes in the NHS. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 22625 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-23more like thismore than 2024-04-23
answer text <p>As part of the consultations on introducing minimum service levels in both ambulance and hospital services, the Department hosted workshops to which a wide range of representative groups were invited. This included employer and provider organisations, and unions representing healthcare professionals.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-04-23T13:50:34.923Zmore like thismore than 2024-04-23T13:50:34.923Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1699131
registered interest false remove filter
date less than 2024-03-26more like thismore than 2024-03-26
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Whooping Cough: Vaccination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure adequate supplies of pertussis vaccine in the context of the rise in instances in the Czech Republic. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 20743 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-15more like thismore than 2024-04-15
answer text <p>The UK Health Security Agency (UKHSA) centrally procures and manages the United Kingdom’s supply of the pertussis vaccine, for the routine national immunisation programmes. Due to the stockpiles maintained in the UK for the national programme, there is good supply available of all pertussis-containing vaccines for the routine immunisation programmes.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-04-15T08:47:34.913Zmore like thismore than 2024-04-15T08:47:34.913Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1697900
registered interest false remove filter
date less than 2024-03-21more like thismore than 2024-03-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Ovarian Cancer: Diagnosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether her Department plans to shorten the diagnostic pathway for ovarian cancer by allowing the CA125 blood test and ultrasound to be undertaken at the same time. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 19930 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-02more like thismore than 2024-04-02
answer text <p>The Department is supporting NHS England in developing Best Practice Timed pathways, to support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard. This standard ensures patients are told they have cancer, or that cancer is ruled out, within 28 days of urgent cancer referral from general practice or screening service.</p><p>In March 2023, NHS England published guidance for local health and care systems to implement a timed gynaecological cancer diagnostic pathway, including for ovarian cancer. The gynaecological pathway ensures that at day zero, when presenting with symptoms, an ultrasound and a minimum data set is obtained, which includes a full blood count. For patients with suspected ovarian cancer, the minimum dataset should also include tumour marker CA125, with confirmation of suspicious features of ovarian cancer on ultrasound.</p><p>The guidance further ensures that patients with persistent abdominal symptoms, raised CA125, and a normal pelvic scan should be referred through the non-specific symptoms rapid diagnostic centre pathway. Women over 50 years old with elevated CA125 and palpable mass or ascites, or both, or with a previous ultrasound with risk of malignancy, should be referred straight to a computed tomography scan.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-04-02T15:37:44.03Zmore like thismore than 2024-04-02T15:37:44.03Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1697901
registered interest false remove filter
date less than 2024-03-21more like thismore than 2024-03-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Ovarian Cancer: Diagnosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 19931 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-28more like thismore than 2024-03-28
answer text <p>Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-03-28T11:38:14.567Zmore like thismore than 2024-03-28T11:38:14.567Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this
1696676
registered interest false remove filter
date less than 2024-03-18more like thismore than 2024-03-18
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Equipment more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of (a) funding and (b) support available for research into non-invasive cancer monitoring technologies. more like this
tabling member constituency Slough more like this
tabling member printed
Mr Tanmanjeet Singh Dhesi remove filter
uin 19142 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-26more like thismore than 2024-03-26
answer text <p>Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23 and the NIHR spends more on cancer than any other disease group.</p><p>In terms of adequacy of funding, the NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p><p> </p><p>Regarding technologies, the NIHR’s Invention for Innovation (i4i) Programme is a translational research funding scheme aimed at supporting medical devices, such as non-invasive cancer monitoring technologies, and includes in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need. Further information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm" target="_blank">https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm</a></p><p>Additionally, in September 2023, the Office for Life Sciences Cancer Mission launched the £12 million NIHR i4i Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call, aiming to support the clinical validation and evaluation of breakthrough technologies that can increase the proportion of cancers that are detected earlier in the disease course and target health inequalities in cancer diagnosis.</p><p>The NIHR continues to welcome and encourage funding applications for research into any aspect of human health, including cancer monitoring technologies, and it is worth noting that all applications that were fundable in open competition, have been funded.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson remove filter
question first answered
less than 2024-03-26T12:01:10.347Zmore like thismore than 2024-03-26T12:01:10.347Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4638
label Biography information for Mr Tanmanjeet Singh Dhesi more like this